HAMPTON, N.J., Sept. 3, 2015 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Chairman and Chief Executive Officer Jonathan Peacock will present at the Rodman and Renshaw Annual Global Investment Conference and participate in the FBR Second Annual Healthcare Conference. Details of the events are as follows:
Rodman and Renshaw Annual Global Investment Conference
Date: September 10, 2015
Location: St. Regis Hotel, New York
Presentation time: 10:50 am ET
FBR Second Annual Conference
Date: September 9, 2015
Location: Four Seasons Hotel, Boston
No presentation. Investor meetings only.
The Rodman and Renshaw presentation will be webcast live and may be accessed under the investor tab at www.bellerophon.com. The webcast will be archived for 90 days.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company is currently developing two product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company intends to commence Phase 3 clinical trials in 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. The Company is also reviewing alternative paths forward for its Bioabsorbable Cardiac Matrix program. For more information, please visit www.bellerophon.com.
CONTACT: At Bellerophon:
At Rx Communications Group:
Bellerophon Therapeutics LLC